Red cell immune function in patients with cancer S

xp574088

Red cell immune function in patients with cancer SAPO-1/Fas, TNF-α, NO experimental study the expression levels of

Chinese papers League finishing. Of: Wang Guanglan, Cao Yang, Zhang long-term, Guo Tong-sheng, Xu Wanqing Key words Tumor Abstract Objective To investigate the immune function in patients with cancer and SAPO-1/Fas, TNF-α, NO expression level of correlation and interaction. Methods Yeast - red cell immune adherence test, 45 patients before chemotherapy and 17 patients were in remission after chemotherapy were red blood cell C3b receptor rosette test (RBC-C3bRR) and RBC immune complex rosette test (RBC-ICR) and ELISA Method 107 patients with cancer and 22 healthy people were SAPO-1/Fas testing, some of which were TNF-α, NO detection. Results SAPO-1/Fas expression levels in cancer patients was significantly higher than the control group (P Key words cancer; SAPO-1/Fas; red blood cell immunity; complement receptor type 1 cells (apoptosis, APO) and red blood cell immune system is the body clear the infection, variation ,[link widoczny dla zalogowanych], aging cells, to maintain their balance in a normal physiological adjustment method; both tumor cells and their associated antigens may directly activate the complement bypass, attracting red blood cell (RBC) 1-type complement receptor (CR1) adhesion of tumor cells and immune-associated antigen and their transport to the liver and spleen reticuloendothelial system and destroyed by macrophages [1]. In recent years, researchers found that APO-1 and its ligand (FasL) is generally considered lethal gene, because they often lead to the expression of the interaction between the cells APO-1 APO been widespread concern. Studies have reported [2], many human malignant tumors showed APO dysfunction. In cancer patients sensitized immune cells such as T lymphocytes and natural killer cells (NK) and other systems through the activation of Fas-mediated cytotoxicity, apoptosis way to clear the tumor cells. Immune cells through their surface expression of FasL with Fas of target cells, making it apoptosis, while the APO-1 binding with FasL and hinder the target cells. And nitric oxide (NO) content in excess may also cause gene mutations and induced tumors. In this study, yeast - red cell immune adherence tests were carried out erythrocyte C3b receptor rosette test (RBC-C3bRR) and RBC immune complex rosette test (RBC-ICR) [3] and the ELISA method SAPO-1/Fas molecules, and on NO concentration and tumor necrosis factor (TNF-α) correlation were analyzed. Now report the results as follows. 1 Materials and methods 1.1 studied 107 cases of cancer patients, male 80 cases, 27 females, mean age of 55.48 years, hospital patients are clinically from 1999 to 2004 and experiment confirm the diagnosis of hospitalized patients. 22 healthy control serum from healthy people, 18 males and 4 females, mean age of 22.27 years. 1.2 Materials 1.2.1 collect all blood samples were collected from the morning fasting, some patients in the blood before and after chemotherapy. Centrifuged at room temperature 3000r/min 10min, serum was stored -20 ℃ (also taking heparin and 1ml for red cell immune adherence test). 1.2.2 Detection of human SAPO-1/Fas SAPO-1/Fas anti-human monoclonal antibody to pre-coated ELISA kit, American Genxyme companies, products purchased from U.S. Biological Engineering Co., Ltd., according to the instructions operation. 1.2.3 Detection of serum TNF-α by double antibody sandwich ELISA, purchased from the bonding company, according to manual operation (self-coated). 1.2.4 Detection of serum NO levels of serum nitrate reductase representatives NO3/NO2 NO concentration. Purchased from Nanjing Jiancheng Institute of Biotechnology, RS-232 produced by the Dutch-type semi-automatic biochemical analyzer. 1.2.5 sensitized material from freeze-dried complement yeast and yeast are not sensitized (by Shanghai Changhai Hospital, Immunology, available). 1.3 Methods 1.3.1 to prepare an access heparinized 1ml, washed with saline 3 times, each time 2000r/min centrifugal 3 ~ 5min, do cell counting and preparation of Application of 1.25 × 107/ml liquid aside. 1.3.2 ready to check complement 2 sensitized and not sensitized yeast polysaccharides all a freeze-dried reagents, the required solution, washed with normal saline were centrifuged 2 times (2000r/min, 4min), red blood cell count, and dubbed in 1 × 108/ml application liquid aside. 1.3.3 Operating take two test tubes, each tube by adding red blood cells application solution 0.05ml. The first tube then add more sugar complement sensitized yeast 0.05ml, the second tube add more sugar is not sensitized yeast 0.05ml, Shake, put at 37 ℃ for 30min. Shake gently removed, 0.1ml saline added to each tube, mixing after each plus 0.25% glutaraldehyde 0.025ml, gently mix, 1 / 3 of volume, the level of smear, dried, methanol fixed , Wright stain, wet mount count at high magnification. A red knot on the two or more than 2 yeast as a wreath. Red blood cell count of 200 to calculate the percentage. The first tube RBC-C3bRR, the second tube for the RBC-ICR. 2 results 2.1 cancer patients and healthy controls and the expression of serum NO content SAPO-1/Fas compared in Table 1. The results showed that the tumor and the expression of serum SAPO-1/Fas NO was significantly higher than healthy control group, and has nothing to do with the type of tumor. Table 1 Cancer patients and healthy control group and the expression of human serum SAPO-1/Fas NO content than the (omitted) Note: The comparison between the various tumor P> 0.05; Compared with control group, P <<0.001 2.2 before and after chemotherapy in cancer patients receiving chemotherapy SAPO-1/Fas levels were measured before and after the SAPO-1/Fas levels of the patients, 17 patients in remission after chemotherapy , the expression level before chemotherapy (8.15 ± 0.11) ng / ml, the expression levels after chemotherapy (7.05 ± 0.59) ng / ml, the paired t test, P <0.05. Tip SAPO-1/Fas levels decreased significantly with disease remission. Part due to disease progression after chemotherapy were fewer cases, were not statistics. 2.3 cancer patients and healthy controls TNF-α levels in cancer patients compared 45 patients with TNF-α levels (6.26 ± 1.74) ng / ml, compared with healthy control group (22 cases) (2.04 ± 0.51 ) ng / ml was significantly higher (P 0.05).